Pulmatrix - נכסים נקיים למניה בודדת PULM

Pulmatrix, Inc. is protected by patents for its drug delivery system, which, combined with strict FDA oversight, creates significant barriers to entry. The company generates revenue by treating patients with lung pathologies through insurance reimbursements and partnerships. Operating within the US legal framework ensures business security. Book value per share data demonstrates capital resilience, while the 0.44 level serves as a critical benchmark.

For Pulmatrix, Inc. (PULM), which is developing the iSPERSE platform and raising capital through licensing deals, the reported book value per share reflects the actual value of net assets per security. This indicator is calculated by dividing equity minus liabilities by the number of shares, allowing the investor to assess the business's internal margin of safety and the risk of overpaying when buying at historical peaks.